Background: Minocycline is recognized as an effective, well-tolerated therapy in rheumatoid arthritis (RA), although its use has been associated with the development of cutaneous hyperpigmentation.
Objectives: To assess the clinical determinants and frequency of minocycline-induced hyperpigmentation in patients with RA.
Methods: A retrospective medical record review of all patients with RA seen in 2 academic rheumatology practices was performed to identify subjects who had received at least 1 month of continuous minocycline therapy.